IMAAVY® (nipocalimab-aahu) Demonstrates Durable, Over Two-Year Disease Control Across a Broad gMG Patient Population Johnson & Johnson has unveiled new clinical findings highlighting the long-term efficacy and safety of IMAAVY® (nipocalimab-aahu) in patients with generalized myasthenia gravis (gMG). The data,…
OrganaBio and RxMP Therapeutics Forge Manufacturing Alliance to Advance Development of RMP-402 Hemostatic Therapy OrganaBio and RxMP Therapeutics have announced a strategic manufacturing partnership aimed at advancing the development of a novel therapy designed to rapidly control severe bleeding. Under…
Shields Health Solutions Collaborates with Columbus Regional Health to Expand Access to Specialty Pharmacy Care Shields Health Solutions, a leading specialty pharmacy integrator and accelerator in the United States, has announced a new strategic partnership with Columbus Regional Health (CRH),…
Pfizer Highlights Oncology Innovation and Advances in Next-Generation Pipeline at ASCO 2026 Pfizer Inc. (NYSE: PFE) has announced an extensive and data-rich presence at the American Society of Clinical Oncology Annual Meeting 2026, scheduled to take place from May 29…
AHF Initiates Statewide Campaign Calling for Full Reinstatement of Florida’s AIDS Drug Assistance Program The AIDS Healthcare Foundation (AHF) has launched a statewide public awareness campaign urging Ron DeSantis and the Florida Legislature to take immediate and permanent action to…
Real Time Medical Systems Highlights New Leadership, AI Solutions, and Expanded Partnership at NAACOS Spring 2026 Real Time Medical Systems (Real Time), a KLAS-rated and HITRUST R2 Certified leader in post-acute care analytics, announced today its participation in the National…
Wound Healing Society Acknowledges Eluciderm, Inc. with Industrial R&D Award for Advancing ELU42 Mechanism of Action Research Eluciderm, Inc., a clinical-stage biopharmaceutical organization focused on the development of innovative small-molecule therapies designed to enhance tissue repair and regeneration, has announced…
Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation aimed at accelerating the development of transformative therapies for LMNA-related…
Palleon Pharmaceuticals Showcases First-in-Class B7-H3–Targeted Sialidase at AACR 2026 Palleon Pharmaceuticals has unveiled new preclinical findings and announced the initiation of a first-in-human clinical trial for its novel oncology candidate E-688/HLX316 during the American Association for Cancer Research Annual Meeting.…
FDA Prioritizes Review of KEYTRUDA® and KEYTRUDA QLEX™ Combinations with Padcev® for Cisplatin-Eligible Muscle-Invasive Bladder Cancer Patients Merck & Co., known as MSD outside the United States and Canada, has announced a significant regulatory milestone as U.S. Food and Drug…
Lundbeck highlights AAN 2026 data showing real-world improvements in migraine-related cognitive symptoms with VYEPTI® (eptinezumab-jjmr) Lundbeck has presented new real-world data from its ongoing INFUSE study at the American Academy of Neurology Annual Meeting 2026, offering fresh insights into the…
Agenus highlights durable survival and immune reprogramming in PD-1 refractory gastroesophageal cancer with Botensilimab combo Agenus Inc., a company focused on advancing immuno-oncology innovation, has reported new clinical findings from an investigator-initiated Phase II study evaluating a multi-agent immunotherapy-based regimen…